Evaluation of a New Commercial Microarray Platform for the Simultaneous Detection of β-Lactamase and mcr-1 and mcr-2 Genes in Enterobacteriaceae

摘要

In this work, we evaluated the performance of the new commercial CT103XL microarray system (Check-Points). In ～6.5 h (starting from culture strains) and for a cost ranging from 50 to 85€, this platform allows the detection of mcr-1 (including the variants from mcr-1.2 to mcr-1.7) and mcr-2 determinants. Along with them, clinically important class A, B, C, and D β-lactamase (bla) genes are simultaneously detected, as in the former version (CT103XL) that has demonstrated an overall accuracy of 94% (7).